Vor Biopharma Inc. (VOR) News
Track canonical SquawkNews coverage tagged to VOR, Vor Biopharma Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 12 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Vor Bio Reports 48-Week gMG Data: 42% Reached MSE
Vor Bio reported post hoc 48-week data from a China Phase 3 gMG study of telitacicept: 42% reached minimal symptom expression at any time; >94% had ≥5-point MG-ADL improvement. Most MSE events were sustained at the next
GEOPOLITICS | Sep 29, 2026, 12:09 PM UTC
L
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
More than 94% of participants achieved a ≥5-point MG-ADL improvement at Week 4842% of telitacicept-treated participants achieved minimal symptom expression (MSE) at any time over 48 weeks, increasing from 23.7% over the
NEWS | Sep 29, 2026, 12:09 PM UTC
M
VOR advances Phase III Telitacicept trials for myasthenia gravis, Sjögren’s
VOR says Telitacicept, a BAFF-APRIL inhibitor, is advancing in Phase III trials for myasthenia gravis and Sjögren’s, citing strong early enrollment and a differentiated B-cell targeting mechanism. Top-line MG data is ant
EQUITY | Sep 09, 2026, 05:06 PM UTC
L
VOR trial update highlights late-stage progress for Telitacicept
Telitacicept is advancing in late-stage trials for myasthenia gravis and Sjögren's disease, with differentiation tied to its dual BAFF-APRIL mechanism and robust safety data from China.
GEOPOLITICS | Sep 09, 2026, 04:30 PM UTC
M
VOR completes Phase III MG trial enrollment; global readout set for 2027
VOR says Phase III MG trial enrollment is completed. A key global readout is expected in 2027, alongside plans for an ocular MG study, with management citing China data on efficacy and durability.
GEOPOLITICS | Sep 08, 2026, 02:01 PM UTC
M
VOR Phase III MG enrollment complete; key readout eyed for early 2027
VOR says enrollment in its Phase III MG trial is complete, with a key readout expected in early 2027. The company also plans an ocular MG study and enhanced dosing convenience.
EQUITY | Sep 08, 2026, 01:27 PM UTC
M
VOR completes Phase III telitacicept enrollment; key readout set for early 2027
VOR says enrollment is complete for its Phase III telitacicept MG trial, with a key readout expected in early 2027. The company is expanding into ocular MG and Sjögren’s, highlighting a dual BAFF/APRIL mechanism.
EQUITY | Sep 08, 2026, 01:10 PM UTC
M
VOR completes Phase 3 UPSTREAM MG enrollment, expands telitacicept to ocular MG
VOR says it completed enrollment in its global Phase 3 UPSTREAM MG trial and expanded its telitacicept global franchise into ocular myasthenia gravis.
EQUITY | Sep 08, 2026, 11:00 AM UTC
L
Vor Bio reports inducement grant under Nasdaq Rule 5635(c)(4)
Vor Bio reports an inducement grant under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 04, 2026, 08:05 PM UTC
L
VOR - Vor Bio To Participate in Upcoming September Conferences
VOR - Vor Bio To Participate in Upcoming September Conferences
EQUITY | Sep 01, 2026, 12:02 PM UTC
L
Vor Biopharma Q2 Adj. EPS Misses Estimate
Vor Biopharma reports Q2 adjusted EPS of $(0.80), missing the $(0.70) estimate
EARNINGS | Aug 11, 2026, 09:30 PM UTC
L
Vor Bio Reports Inducement Grant
Vor Bio grants inducement award
EQUITY | Aug 03, 2026, 08:30 PM UTC